# Delirium Management Guideline

**Division of Acute Care Surgery**  
*Revised: May 2024*

---

## 1. Monitoring and Initial Assessment

- **CAM-ICU (Confusion Assessment Method for ICU)** should be documented each shift and reviewed during rounds.
  - **Only report as "Unable to Assess" if RASS < -3**
  - If CAM-ICU is positive, evaluate for possible causes:
    - Hypoxia
    - Sepsis
    - Congestive Heart Failure (CHF)
    - Over-sedation
    - Deliriogenic medications

---

## 2. Delirium Classification and Initial Management

### A. Hypoactive Delirium  
(CAM-ICU positive and RASS 0 to -3)

- Prioritize **non-pharmacologic management**
- Minimize or discontinue sedating medications

### B. Hyperactive or Mixed Delirium  
(CAM-ICU positive and RASS -3 to +4)

- See pharmacologic algorithm (Section 4)
- Ensure **goal RASS** is clearly defined for all patients

---

## 3. Non-Pharmacologic Interventions

### A. Orientation and Stimulation
- Provide visual and hearing aids
- Reorient frequently
- Encourage communication
- Maintain sleep hygiene
- Provide cognitive stimulation during daytime

### B. Environment Optimization
- Mobilize early and frequently
- Place familiar objects in the room
- Minimize overnight noise
- Remove unnecessary lines and drains

### C. Supportive Measures
- Daily Spontaneous Awakening Trials (SATs)
- Adequate pain management
- Correct dehydration and electrolyte imbalances

---

## 4. Deliriogenic Medications to Minimize or Avoid

- Benzodiazepines  
- Anticholinergics:
  - Diphenhydramine, Glycopyrrolate, Metoclopramide
  - H2 blockers, TCAs, Cyclobenzaprine  
- Steroids  
- Opioids (if not the primary cause of pain)
  - **Taper dose and use multimodal pain control**

---

## 5. Hyperactive Delirium Management Algorithm

### CAM-ICU Positive with RASS +1 to +2

- Ensure pain control and sleep hygiene
- Initiate:
  - **Quetiapine** 25–50 mg q8–12h  
  - OR **Olanzapine** 2.5 mg q8–12h  
- **Haloperidol** 1–10 mg IV q4h PRN for breakthrough agitation

### CAM-ICU Positive with RASS +3 to +4

#### If Extubated:

- Ensure adequate pain control
- Haloperidol 5–20 mg IV/IM q15min PRN for extreme agitation
- If no response at 24 hrs or multiple IV haloperidol doses:
  - Reassess analgesia
  - Increase Quetiapine to 50–100 mg q6–8h or Olanzapine to 5–10 mg q6–8h
  - Continue haloperidol for breakthrough

#### If Intubated/Trached:

- Start sedative infusion (if not already infusing)
  - Bolus or titrate up current sedative (e.g., propofol)
- Ensure pain control
- Haloperidol 5–20 mg IV/IM q15min PRN for extreme agitation
- Consider **Dexmedetomidine**

---

### If No Response After 48 Hours

- RASS remains ≥ +3 with repeated IV haloperidol:
  - Reassess pain control
  - Change atypical antipsychotic
  - Consider alternate sedative
- Adjust to **CAM +, RASS +1 to +2** or **+3 to +4** pathways as appropriate

---

## 6. Special Populations and Considerations

### A. Geriatrics (> 65 years)

- Reduce initial doses of:
  - Antipsychotics  
  - Depakote (Valproic acid)
- Avoid:
  - Haloperidol >5 mg
  - Quetiapine >100 mg
- Consider:
  - **Trazodone** 25–50 mg qHS before antipsychotics if insomnia-related agitation

### B. General

- **Maximize one agent** before switching or adding others
- Refractory cases:
  - Trial **Geodon** (Max: 40 mg BID)
  - If still uncontrolled → **Psychiatry consult**
- Monitor QTc:
  - Modify therapy if **QTcF > 500 ms**

---

## 7. Traumatic Brain Injury (TBI)

- Initiate **Valproic acid (Depakote)** 250–500 mg q8–6h  
  - Titrate up to **60 mg/kg/day** as needed

- Consider early **Propranolol** 10–20 mg q8–6h  
  - Max: **360 mg/day**  
  - Useful in neurologic storming

- Avoid high-dose haloperidol

#### Valproate Monitoring:
- Obtain baseline and **weekly LFTs**
- Discontinue if:
  - AST or ALT >5× ULN  
  - Alk Phos >2× ULN (on 2 occasions)  
  - T. Bili >2.5 mg/dL with other LFT abnormalities  
  - INR >1.5 with elevated transaminases

- Use caution in hepatic disease
- Check valproate levels only if **toxicity suspected**

---

## 8. References

1. Devlin JW, Skrobik Y, Gélinas C, et al. *Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Guidelines.* Crit Care Med. 2018; 46:825–873.  
2. Girard T, Exline M, Carson S, et al. *Haloperidol and Ziprasidone in Delirium.* N Engl J Med. 2018; 379(26):2506–2516.  
3. Hughes CG, Mailloux PT, Devlin JW, et al. *Dexmedetomidine vs. Propofol in Sepsis.* NEJM. 2021; 384:1424–1436.  
4. Marra A, Wesley E, Pandharipande P, et al. *The ABCDEF Bundle in Critical Care.* Crit Care Clin. 2017; 33(2):225–243.  
5. Plantier D, Luauté J, et al. *Drug Therapy for TBI Behavior Disorders.* Ann Phys Rehabil Med. 2016; 59(1):42–57.  
6. Williamson D, Frenette A, et al. *Agitation in TBI: Systematic Review.* BMJ Open. 2019; 9:e029604  

---

## 9. Authors

- **Jill Streams, MD**  
- **Bradley Dennis, MD**  
- **Abby Luffman, MSN, APN, AGACNP-BC**  
- **Bethany Evans, RN, MSN, ACNP-BC**  
- **Leanne Atchison, PharmD**
